Laidlaw initiated coverage on Nuvectis Pharma with a new price target
$NVCT
Biotechnology: Pharmaceutical Preparations
Health Care
Laidlaw initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $19.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2025 | $17.00 | Buy | Maxim Group |
| 3/17/2025 | $19.00 | Buy | Laidlaw |
| 7/13/2022 | $21.00 | Buy | Ladenburg Thalmann |
| 3/2/2022 | $14.00 | Buy | HC Wainwright & Co. |